Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 2/20 | 0.33 |
| ▸ | RARB | P10826 | 2/20 | 0.33 |
| ▸ | RARG | P13631 | 2/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.33 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12366160 | 0.88 | ABL1 (0.41) | ABL1MAPK1MAP2K4 | |
| SCHEMBL12366604 | 0.85 | HTR5A (0.41) | — | |
| SCHEMBL12365904 | 0.84 | BCL2L1 (0.45) | TDP1MAP4K4ARRARARARB | |
| SCHEMBL12366209 | 0.82 | TDP1 (0.40) | TDP1RARARARBRARGMAPK1 | |
| SCHEMBL12366261 | 0.81 | TDP1 (0.39) | TDP1ARMAPK1 | |
| SCHEMBL12366134 | 0.80 | KMO (0.49) | TDP1ABL1AR | |
| SCHEMBL12365222 | 0.80 | TDP1 (0.44) | TDP1ARRARARARBRARG | |
| SCHEMBL12366167 | 0.79 | TDP1 (0.42) | TDP1ARRARARARBRARG | |
| SCHEMBL12366145 | 0.77 | TDP1 (0.40) | TDP1DHODHMAPK1 | |
| SCHEMBL12365914 | 0.77 | KDM4A (0.40) | TDP1RARBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | TDP1 378/4885MAP4K4 4109/4885ABL1 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.